Biosimilars move to centre stage
This article was originally published in Scrip
If anyone had any doubts that biosimilars are going to have a starring role in the future development of the pharmaceuticals industry they will have had them challenged by the sight of Pfizer signing a $200 million plus deal with India's Biocon and the fact that the FDA will be airing its thoughts on an approval pathway for such drugs at a public meeting on the 2nd and-3rd of November.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.